Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00793780 · ClinicalTrials.gov registry record · NA

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

A NA study of Obesity and Schizophrenia, sponsored by Yale University.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT00793780: Completed NA study of Obesity and Schizophrenia, sponsored by Yale University.

NCT00793780 is a NA study of Obesity and Schizophrenia that has completed, run by Yale University. The registered enrollment target is 24 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00793780, a NA study of Obesity and Schizophrenia, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to find out how effective low dose oral naltrexone is on reducing body weight when compared to placebo in women with schizophrenia and schizoaffective disorder.

Primary Outcome

Weight was measured with shoes off to the nearest 0.1 kg.

Interventions

  • OTHER Placebo
  • DRUG Naltrexone 25mg

Study Locations (1)

Connecticut

  • Connecticut Mental Health Center - New Haven

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-12
Est. Completion 2010-11
Phase NA
Yale University

1,492 total trials

What the finished NCT00793780 record still lists

NCT00793780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00793780 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00793780 about?

NCT00793780 is a clinical study titled "Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia". The purpose of this clinical trial is to find out how effective low dose oral naltrexone is on reducing body weight when compared to placebo in women with schizophrenia and schizoaffective disorder.

What is the current status of trial NCT00793780?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2008-12. Estimated completion is 2010-11.

What conditions does trial NCT00793780 study?

This clinical trial studies the following conditions: Obesity, Schizophrenia, Schizoaffective Disorder.

What interventions are being tested in trial NCT00793780?

The interventions under investigation include: Placebo (OTHER), Naltrexone 25mg (DRUG).

Who is sponsoring clinical trial NCT00793780?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00793780 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00793780's enrollment target sits among peer trials

24 909th of 1053 higher than 127 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00793780, the US trial registry maintained by the National Library of Medicine. NCT00793780 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.